Articles tagged with Crohn Disease
Researchers developed nanoparticles that mimic the glycocalyx pattern to treat inflammatory bowel disease. The treatment reduced symptoms and inflammation in mice with IBD, with specific versions showing significant improvement.
Researchers have developed a microgel delivery system that keeps beneficial bacteria safe while actively clearing out harmful ones in the gut. In mice, this system treated intestinal inflammation without side effects and showed promise as a viable treatment strategy for intestinal diseases.
Research by West Virginia University professor Sean Tu found that orphan drugs earn pharmaceutical companies almost as much as those marketed to the general public. The Orphan Drug Act incentivizes companies with tax credits, longer patent exclusivity, and easier FDA review for treating rare diseases.
A new study suggests that high-sugar diets can exacerbate inflammatory bowel disease (IBD) symptoms by disrupting the colon's lining renewal process. The research found that a high-sugar diet led to impaired cell division and altered metabolic pathways in mice, resulting in faster gut damage.
Researchers developed human calprotectin ligands based on peptides to detect and quantify the protein in stool samples or serum levels, offering a more accurate and controlled way of detecting biomarkers.
Researchers at MIT have designed new 'smart' sutures that can deliver drugs or sense inflammation after surgery. The bioderived sutures use hydrogel coatings to detect early warning signs of complications, such as Crohn's disease, and can also release therapeutic molecules to promote healing.
A study published in Cell Reports Medicine found that pro-inflammatory cell types dominate the intestinal mucosa of children with inflammatory bowel disease, while protective cells are underrepresented. The results provide new insights into the immunology of IBD and may lead to the development of more effective treatments.
A study published in Microorganisms shows that melatonin can aggravate Crohn's disease and ulcerative colitis by disrupting the balance of gut microbiota. The hormone, commonly used to improve sleep, had negative effects on bowel inflammation in laboratory mice, depending on their microbiota profile.
A new study by UCL researchers hints at the possibility of detecting conditions such as coeliac disease and Parkinson's disease in principle up to 10 years before diagnosis. The review of existing evidence indicates a 'diagnostic window' – the point at which diagnosis may be possible for some patients.
A new Cochrane Review found that stool transplantation can increase the number of people recovering from Clostridioides difficile (C. diff) infection by 77%, compared to 40% with standard antibiotic treatment. The study also showed a decrease in side effects with stool transplantation.
Researchers at Cedars-Sinai Medical Center identified a genetic variant associated with increased risk of developing perianal Crohn's disease, a debilitating manifestation of Crohn's disease. The study highlights the importance of targeting the alternative complement pathway and Complement Factor B (CFB) in treating this condition.
Patients with inflammatory bowel disease (IBD) are at a higher risk of developing lymphoma, particularly those with Crohn's disease. The risk is driven by both the disease activity and treatment, including immunomodulating drugs.
A UC Riverside-led study found that reduced PTPN2 activity in intestinal epithelial cells leads to decreased Paneth cell antimicrobial peptide production, disrupting the gut microbiota and increasing E. coli. This loss can serve as a marker of IBD disease.
A new imaging technique using a novel nuclear medicine tracer has been developed to improve the treatment of intestinal strictures in Crohn's disease patients. The technique allows for precise differentiation between inflammation and fibrosis, enabling targeted therapy.
Researchers found that a combination of IL-22 and IL-1R inhibitors could be a promising treatment for inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The study suggests that targeting both pathways may lead to more effective treatment outcomes.
Researchers from the University of North Carolina Health Care announce that patients receiving anti-TNF biologic treatments combined with methotrexate had better outcomes than those treated with adalimumab alone. The study, published in Gastroenterology, provides clear results that can immediately impact patient care.
Researchers at Mayo Clinic found that a dissolvable plug delivering stem cells can heal single-tract fistulas in patients with Crohn's disease. The treatment has shown durable results with minimal side effects, offering hope for patients with refractory perianal fistulas.
Researchers at Karolinska Institutet have developed a new approach to treating inflammatory diseases by analyzing the activity of genes in individual cells. This digital twin technology could lead to personalized drug therapies for patients with conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
A new study found that individuals with a normal gastrointestinal biopsy still have a higher risk of developing inflammatory bowel disease (IBD) in the years following the biopsy. The study of over 450,000 individuals in Sweden showed that symptoms of IBD may start significantly before the disease shows up on biopsy.
Researchers have isolated two new bacterial species from patients with inflammatory bowel disease (IBD), which break down the protective mucus layer of the gut. The bacteria, Allobaculum mucilyticum and Allobaculum fili, are highly efficient at degrading intestinal mucus, leading to potent immune responses.
Research suggests that frequent antibiotic use may heighten the risk of inflammatory bowel disease among older adults. The study found a cumulative risk, with the highest risk observed 1-2 years after antibiotic exposure, particularly for those targeting gut infections.
Salk scientists have developed a new therapeutic compound called FexD, which reverses gut inflammation in mouse models of inflammatory bowel disease. By activating the master regulator protein FXR, FexD reduces inflammation and restores balance to the digestive system.
A large international study found that adopting and maintaining a healthy lifestyle may prevent up to 60% of Crohn's disease and ulcerative colitis cases. The study analyzed data from over 300,000 participants and estimated that a low risk score for inflammatory bowel disease could have prevented a significant proportion of cases if an...
Researchers at Karolinska Institutet have shown that B cells can prevent intestinal healing by increasing in numbers after bowel damage. The study found that mice lacking B cells recovered more quickly after bowel damage than regular mice.
Researchers discover how E. coli bacteria manipulate the immune system to cause ileocolitis in susceptible individuals. The study reveals the key role of agr2-associated ER stress in promoting dysbiosis and triggering CD103+ dendritic cell IL-23-dependent inflammation.
Researchers at the University of Wisconsin-Madison develop nanoparticles to neutralize molecules implicated in IBD, significantly improving treatment outcomes. The probiotic bacteria are equipped with nano-backpacks that target reactive oxygen species, reducing inflammation and promoting weight gain and colon length restoration.
A study by the University of Gothenburg found that women with inactive inflammatory bowel disease (IBD) have a higher risk of giving birth prematurely, particularly if they have microscopic inflammation in their intestinal mucosa. This association was not seen for other adverse pregnancy outcomes, such as growth restriction.
Researchers at UCalgary have discovered a potential new treatment for fibrosis, a condition that causes thickening of the gut wall and life-threatening blockage in people with Crohn's disease and ulcerative colitis. The study suggests that drugs targeting specific sensors may prevent inflammation-associated gut blockage.
Researchers have discovered that mutations in mitochondrial-related genes can trigger hyperinflammation, leading to diseases such as Crohn's disease and tuberculosis. The study found that these mutations lead to a new type of cell death called necroptosis, which causes an aggressive inflammatory immune response.
The study reveals that the small intestinal microbiome is unstable and changes in response to diet, but certain species persist and adapt through subspecies changes. The findings have important implications for understanding intestinal diseases such as celiac disease and Crohn's disease.
Researchers at UVA Children's will use a sophisticated computer model to better understand and treat Crohn's disease, which can have lifelong consequences for young patients. The team hopes to identify biological markers or metabolic signatures that can be used for early diagnosis and personalized medicine.
Researchers at Weill Cornell Medicine found that gut pain-sensing neurons regulate the microbial community in the intestines, boosting beneficial microbes to protect against inflammation. The study suggests that targeting these neurons could lead to new anti-inflammatory treatments for IBD and other disorders.
Researchers found that certain types of dietary fiber cause inflammation in IBD patients, worsening symptoms. A stool test is being developed to predict individual responses to dietary fibers, enabling tailored recommendations.
A new study found that a protein called apoptosis inhibitor five (API5) protects most people with the mutation linked to Crohn's disease from developing the illness. Norovirus infection blocks API5 production in mice with Crohn's, killing gut-lining cells and tipping the balance towards autoimmune disease.
A cohort study found that endoscopists performing colonoscopies in FIT-based screening programs should aim for markedly higher ADRs compared to primary colonoscopy screening. The study suggests that high ADRs are associated with lower colorectal cancer incidence and mortality. Researchers recommend using ADR targets, including differen...
A recent study published in the journal Gut found that gay men are more than twice as likely to develop inflammatory bowel disease (IBD) than heterosexual men who engage in high-risk sexual activity. The study's lead author notes that this finding will open a new field of research into gastrointestinal inflammatory conditions.
A recent study has identified genetic variants in 10 genes that elevate a person's susceptibility to Crohn's disease, a form of inflammatory bowel disease. The research highlights the causal role of mesenchymal cells in intestinal inflammation, shedding light on the genetic roots of inflammatory bowel disease.
A new study by Massachusetts General Hospital researchers suggests that certain anti-cancer drugs may target a key player in Crohn's disease, a type of inflammatory bowel disease. The study found that mutations in a specific chromatin reader, SP140, are associated with an increased risk of immune diseases like Crohn's.
A large population study found a 14% increased risk of developing Crohn's disease among children born via cesarean section. The study suggests an association between cesarean section and altered gut microbiome, warranting further research.
A new study of over 8 million pregnancies found that pregnant women with inflammatory bowel disease (IBD) are at a higher risk of gestational diabetes, postpartum hemorrhage, and other complications. IBD can also lead to longer hospital stays and increased medical costs.
Researchers developed an AI system that classifies IBDN lesions accurately, displaying image-based diagnostic ability with 64.5% sensitivity and 89.5% specificity. The correct diagnosis rate of the AI system was 79.0, surpassing that of endoscopists, who achieved a 77.8% accuracy rate.
A recent study at Cedars-Sinai Medical Center found that biologic drugs for inflammatory bowel disease may improve the T-cell immune response in patients vaccinated against COVID-19. This could potentially offer protection against severe disease. The study suggests that these treatments may be used to monitor vaccine and booster outcomes.
Researchers identified a blood biomarker that predicts severe Crohn's disease and is detectable up to seven years prior to diagnosis. The biomarker neutralizes protective effects of a cytokine, leading to intestinal damage and weakening the immune system.
A new study found that exposure to dogs, particularly from ages 5 to 15, was linked to healthy gut permeability and balance in the gut microbiome. Additionally, growing up in a large family with three or more siblings may also provide protection against Crohn's disease by influencing microbiome composition.
A study of 2.3 million patient records found that antibiotic use was associated with a higher risk of developing inflammatory bowel disease in older adults. The risk increased substantially with each course of antibiotics, with patients who received five or more courses being over 2.3 times more likely to be diagnosed with the condition.
A new study suggests that growing up with dogs and in large families may lower the risk of inflammatory bowel disease. Exposure to dogs, particularly between ages 5-15, was linked to healthy gut permeability and a balanced immune response, which may help protect against Crohn's disease.
A study of 2.3 million patient records found that antibiotic use was associated with a higher risk of developing inflammatory bowel disease in seniors, particularly those who received multiple courses. The risk increased substantially with each course of antibiotics prescribed.
An artificial intelligence model trained on histological images of surgical specimens accurately classified patients with and without Crohn disease recurrence. The model revealed previously unrecognized differences in adipose cells and mast cell infiltration, enabling stratification by prognosis for postoperative Crohn disease patients.
Research finds that intestinal inflammation liberates chemicals that nourish E. coli's growth and promote inflammation, highlighting new treatment targets for Crohn's disease. The study identifies key compounds that feed E. coli, such as phospholipids and amino acids, and shows that these compounds can enhance the bacteria's virulence.
Researchers analyzed genomic profiles of over one million cells from 1,000 people, identifying a link between specific genes and immune cell types in autoimmune diseases. The discovery could lead to tailored treatments and refine clinical trials.
A team led by Case Western Reserve University discovered the novel repair properties of Gasdermin B protein, promoting restoration of epithelial layers and effective wound-healing. The findings have significant implications for designing therapeutics to enhance wound repair in various organs.
Researchers discovered a key growth factor protein, HB-EGF, produced by immune-regulating cells that protects the gut against inflammatory bowel disease. ILC3s produce HB-EGF to counteract TNF-induced inflammation and maintain gut barrier function.
A recent study by researchers at Case Western Reserve University found that Candida tropicalis fungus can trigger chronic inflammation in the gut microbiome of Crohn's disease patients. This imbalance of fungi and bacteria can create a predisposition to inflammatory bowel disease.
Researchers discovered that people with inflammatory bowel disease (IBD) have higher levels of microplastics in their feces compared to healthy individuals. The study suggests a possible link between microplastic exposure and IBD, but the exact relationship remains unclear.
Researchers at UC Riverside have discovered that targeting the TNFR1 receptor may be a more effective approach to treating inflammatory bowel disease. By selectively blocking TNFR1, they found significant benefits in mice with Crohn's-like ileitis, suggesting this approach could offer a new opportunity for healing.
A study by Weill Cornell Medicine investigators found that antibodies secreted in the gut help control pathogenic forms of gut fungi like Candida albicans. However, patients with Crohn's disease often have impaired antibody function, leading to an overgrowth of harmful fungi.
A McMaster University-led study found that stress hormones suppress the innate immune system, which normally protects the gut from harmful bacteria like E. coli linked to Crohn's disease. Removing stress hormones restored proper function to immune cells and epithelial cells, blocking invasion of microbes.
Researchers have identified a link between certain gut microbiome molecules and the immune system protein P-gp, which plays a critical role in gut inflammation. The study suggests that supporting a healthy balance of microbes in the gut may help regulate P-gp expression and prevent chronic inflammation.
Researchers found that glial cells are activated by interferon gamma in response to pathogen invasion, releasing signals to attract immune cells to fight infection. In the absence of disease or injury, blocked activation led to tissue inflammation, highlighting their role in maintaining healthy intestinal tissue.
A study by University of Limerick researchers has found that Crohn's disease is associated with higher depositions of fat in the abdominal areas where the intestines are located. This suggests a direct link between fatty tissue and Crohn's disease, potentially leading to new diagnostic tests and treatments.